AlloVir, a Phase 2 biotech developing allogeneic T cell therapies for viral diseases, filed on Monday with the SEC to raise up to $100 million in an initial public offering.
The company's pipeline contains lead candidate Viralym-M, a multi-virus-specific T cell therapy targeting five viruses. The company is initially focusing on immunocompromised allogeneic hematopoietic stem cell transplant (HSCT) and solid organ transplant patients who are at high risk for life-threatening viral infections from the five viruses targeted by Viralym-M. AlloVir recently reported positive data from its completed a Phase 2 trial and plans to initiate a total of three Phase 3 pivotal and three Phase 2 trials in 2020 and 2021.
The Cambridge, MA-based company was founded in 2013 and plans to list on the Nasdaq under the symbol ALVR. AlloVir filed confidentially on June 3, 2020. Morgan Stanley, J.P. Morgan, SVB Leerink, and Piper Sandler are the joint bookrunners on the deal. No pricing terms were disclosed.
